ArticleDrug design, development and therapy2025
Noninferiority of 0.25% versus 0.375% Ropivacaine in Popliteal Sciatic and Saphenous Nerve Blocks for Analgesia After Foot and Ankle Surgery: A Randomized Self-Paired Noninferiority Trial.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Liposomal bupivacaine versus ropivacaine in four-in-one nerve block for total knee arthroplasty: a randomized controlled trial.BMC anesthesiology · 2026Trial
- Liposomal bupivacaine for popliteal sciatic and saphenous nerve blocks in patients undergoing foot and ankle surgery: a single-center, double-blind, randomized controlled trial.Frontiers in medicine · 2026Trial
- Rescue Saline Washout for Popliteal Sciatic Block.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Peripheral nerve blocks are an important part of postoperative analgesia for the extremities. Previously, we reported that a single shot of 0.375% ropivacaine (20 mL) via ultrasound-guided popliteal sciatic and saphenous nerve blocks provided satisfactory analgesia after foot and ankle surgery; however, toe and ankle weakness in the early postoperative period became a concern for patients. Our preliminary data indicate that 0.25% ropivacaine may be effective for postoperative analgesia. Hence, we hypothesized that the analgesic effect of 0.25% ropivacaine would be noninferior to that of 0.375% ropivacaine at the same volume and would reduce the degree of weakness. Patients and Methods: In this randomized, double-blind, self-paired, noninferiority trial, 31 patients who were scheduled for similar, elective, bilateral foot and ankle surgeries under general anesthesia combined with popliteal sciatic and saphenous nerve blocks were enrolled. Each patient was randomly assigned to receive 0.25% ropivacaine on one side and 0.375% ropivacaine on the other side. The primary outcome was the duration of analgesia, which was defined as the time from the end of the nerve blocks until the first sensation of pain in the surgical area, as indicated by a patient-reported visual analog scale (VAS) score ≥ 1. The secondary outcomes included static VAS scores, motor and sensory block grades, patient satisfaction scores, and the incidence of adverse effects. Results: The mean duration of analgesia was 31.7 ± 8.3 h for 0.25% ropivacaine, and 31.9 ± 8.5 h for 0.375% ropivacaine (duration difference, -0.16; 95% CI, -1.5 to 1.2; Conclusion: The results revealed that 0.25% ropivacaine is not inferior to 0.375% ropivacaine in terms of the analgesic duration of popliteal sciatic and saphenous nerve blocks for bilateral foot and ankle surgery. Moreover, 0.25% ropivacaine reduced the incidence of motor block. Therefore, we recommend 0.25% ropivacaine for postoperative analgesia for foot and ankle surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.